Literature DB >> 26055383

In Vitro Antimalarial Activity of Different Inhibitors of the Plasmodial Isoprenoid Synthesis Pathway.

Marcia F da Silva1, Alexandre Y Saito1, Valnice J Peres1, Antonio C Oliveira2, Alejandro M Katzin3.   

Abstract

Previous studies have shown that fosmidomycin, risedronate, and nerolidol exert antimalarial activity in vitro. We included squalestatin, an inhibitor of the isoprenoid metabolism in Erwinia uredovora, and found that combinations of compounds which act on different targets of the plasmodial isoprenoid pathway possess important supra-additivity effects.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26055383      PMCID： PMC4505249          DOI： 10.1128/AAC.04161-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Isobolographic analysis of non-depolarising muscle relaxant interactions at their receptor site.

Authors:  Matthias Paul; Christoph H Kindler; Ralf M Fokt; Natalie C J Dipp; C Spencer Yost
Journal:  Eur J Pharmacol       Date:  2002-03-01       Impact factor: 4.432

2.  Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum.

Authors:  Quinton L Fivelman; Ipemida S Adagu; David C Warhurst
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  Characterization of the isoprenoid chain of coenzyme Q in Plasmodium falciparum.

Authors:  Cristiana Santos de Macedo; Maria Laura Uhrig; Emilia A Kimura; Alejandro Miguel Katzin
Journal:  FEMS Microbiol Lett       Date:  2002-01-22       Impact factor: 2.742

Review 4.  Statistical analysis of drug-drug and site-site interactions with isobolograms.

Authors:  R J Tallarida; F Porreca; A Cowan
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

5.  Human malaria parasites in continuous culture.

Authors:  W Trager; J B Jensen
Journal:  Science       Date:  1976-08-20       Impact factor: 47.728

6.  In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin.

Authors:  Jochen Wiesner; Dajana Henschker; David B Hutchinson; Ewald Beck; Hassan Jomaa
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

7.  Terpenes arrest parasite development and inhibit biosynthesis of isoprenoids in Plasmodium falciparum.

Authors:  Herbert Rodrigues Goulart; Emília A Kimura; Valnice J Peres; Alicia S Couto; Fulgencio A Aquino Duarte; Alejandro M Katzin
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 8.  Designing the next generation of medicines for malaria control and eradication.

Authors:  Jeremy N Burrows; Rob Hooft van Huijsduijnen; Jörg J Möhrle; Claude Oeuvray; Timothy N C Wells
Journal:  Malar J       Date:  2013-06-06       Impact factor: 2.979

9.  Inaugural meeting of the malaria policy advisory committee to the WHO: conclusions and recommendations.

Authors: 
Journal:  Malar J       Date:  2012-05-31       Impact factor: 2.979

10.  Cloning and characterization of bifunctional enzyme farnesyl diphosphate/geranylgeranyl diphosphate synthase from Plasmodium falciparum.

Authors:  Fabiana M Jordão; Heloisa B Gabriel; João M P Alves; Claudia B Angeli; Thaís D Bifano; Ardala Breda; Mauro F de Azevedo; Luiz A Basso; Gerhard Wunderlich; Emilia A Kimura; Alejandro M Katzin
Journal:  Malar J       Date:  2013-06-04       Impact factor: 2.979
View more
  2 in total

1.  Exploring Ubiquinone Biosynthesis Inhibition as a Strategy for Improving Atovaquone Efficacy in Malaria.

Authors:  I B Verdaguer; M Crispim; C A Zafra; R A C Sussmann; N L Buriticá; H R Melo; M F Azevedo; F G Almeida; E A Kimura; A M Katzin
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

2.  Plasmodium falciparum parasites overexpressing farnesyl diphosphate synthase/geranylgeranyl diphosphate synthase are more resistant to risedronate.

Authors:  Heloisa B Gabriel; Mauro F Azevedo; Emília A Kimura; Alejandro M Katzin
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-08-13       Impact factor: 2.743
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.